Imran A. Nizamuddin

Hematology

4440 W 95th St Fl 8
Oak Lawn, IL 60453

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy.

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy.

Journal: Blood cancer journal

Published: December 12, 2025

Prognosis and Treatment of Plasmablastic Lymphoma in the United States: A Multicenter Retrospective Study.

Prognosis and Treatment of Plasmablastic Lymphoma in the United States: A Multicenter Retrospective Study.

Journal: Research square

Published: November 19, 2025

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Journal: Blood advances

Published: September 24, 2025

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Journal: Blood advances

Published: September 24, 2025

Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell Lymphoma.

Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell Lymphoma.

Journal: Blood advances

Published: September 24, 2025

Prognosis and treatment of plasmablastic lymphoma in the United States: a multicenter retrospective study.

Prognosis and treatment of plasmablastic lymphoma in the United States: a multicenter retrospective study.

Journal: Blood cancer journal

Published: September 13, 2025

Treatment-related Outcomes and Patterns of Relapse in Secondary CNS Involvement by Large B-cell Lymphoma.

Treatment-related Outcomes and Patterns of Relapse in Secondary CNS Involvement by Large B-cell Lymphoma.

Journal: Blood

Published: September 02, 2025

Clinical and Molecular Differences Suggest Different Responses to Immune Checkpoint Inhibitors in Microsatellite-Stable Solid Tumors with High Tumor Mutational Burden.

Clinical and Molecular Differences Suggest Different Responses to Immune Checkpoint Inhibitors in Microsatellite-Stable Solid Tumors with High Tumor Mutational Burden.

Journal: Cancers

Published: June 30, 2025

Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibody Use in Earlier Lines of Treatment of Large B-Cell Lymphoma, Follicular Lymphoma, and Mantle Cell Lymphoma.

Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibody Use in Earlier Lines of Treatment of Large B-Cell Lymphoma, Follicular Lymphoma, and Mantle Cell Lymphoma.

Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

Published: May 30, 2025

BV and beyond: how to incorporate novel agents into PTCL management.

BV and beyond: how to incorporate novel agents into PTCL management.

Journal: Hematology. American Society of Hematology. Education Program

Published: December 07, 2024

Large B cell lymphoma microenvironment archetype profiles.

Large B cell lymphoma microenvironment archetype profiles.

Journal: Cancer cell

Published: November 15, 2024

Bispecific antibodies in follicular lymphoma.

Bispecific antibodies in follicular lymphoma.

Journal: Haematologica

Published: August 16, 2024

Showing 1-12 of 23

Last Updated: 09/26/2026